PTGX
Protagonist Therapeutics, Inc.
Biotechnology · Healthcare · United States
151.42
close · 2026-08-13
value
4
cheaper than peers4
quality
93
stronger fundamentals93
ranked against
Biotechnology (commercial)
value
quality
101 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 11.64× | 22 |
| price to sales | 127.45× | 12 |
| forward P/E | 1128.76× | 1 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 1.5% | 89 |
| revenue growth | 99.0% | 77 |
| operating margin | -6.5% | 68 |
| return on equity | -17.1% | 65 |
4 of 4 measures available
Facts
| market cap | $10B |
| free cash flow | -$77.7M |
| employees | 131 |
| first trade | 2016-08-11 |
| next earnings | 2026-08-05 |
| fundamentals updated | 2026-08-07 |